Qatar vs Sweden: Reported rate of new cervical cancer cases
Qatar
8.72 per 100,000 women
in 2017
Sweden
7.48 per 100,000 women
in 2022
Qatar rank
23rd
Sweden rank
25th
Reported rate of new cervical cancer cases over time
- Qatar
- Sweden
How they compare
Qatar currently reports 8.72 per 100,000 women against 7.48 per 100,000 women in Sweden, a difference of 1.24 per 100,000 women.
That makes Qatar's figure about 1.2 times Sweden's.
The two have swapped places 3 times across 15 shared years of data; in 2003 it was Qatar ahead.
Qatar ranks 23rd and Sweden ranks 25th of 46 countries.
Sweden has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Qatar | Sweden | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 5.82 per 100,000 women | 6.99 per 100,000 women | 1.18 per 100,000 women | Sweden |
| 2010s | 4.35 per 100,000 women | 8.16 per 100,000 women | 3.81 per 100,000 women | Sweden |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher reported rate of new cervical cancer cases, Qatar or Sweden?
- Qatar, at 8.72 per 100,000 women against 7.48 per 100,000 women in Sweden as of 2017.
- What is the difference in reported rate of new cervical cancer cases between Qatar and Sweden?
- 1.24 per 100,000 women, with Qatar ahead.
- How many years of comparable data are there for Qatar and Sweden?
- 15 years are reported by both, from 2003 to 2017.
- How do Qatar and Sweden rank globally for reported rate of new cervical cancer cases?
- Qatar ranks 23rd and Sweden ranks 25th of 46 countries.
- Where does this data come from?
- Global Cancer Observatory (2025) β processed by Our World in Data, published as Reported rate of new cervical cancer cases. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Reported number of new cervical cancer cases per 100,000 women, based on data from cancer registries. Comparisons may be affected by differences in measurement, including screening and diagnosis.